AIM
Price
$2.68
Change
-$0.20 (-6.94%)
Updated
Sep 26 closing price
Capitalization
7.26M
URGN
Price
$18.34
Change
+$1.08 (+6.26%)
Updated
Sep 26 closing price
Capitalization
848.48M
50 days until earnings call
Interact to see
Advertisement

AIM vs URGN

Header iconAIM vs URGN Comparison
Open Charts AIM vs URGNBanner chart's image
AIM ImmunoTech
Price$2.68
Change-$0.20 (-6.94%)
Volume$131.87K
Capitalization7.26M
UroGen Pharma
Price$18.34
Change+$1.08 (+6.26%)
Volume$1.2M
Capitalization848.48M
AIM vs URGN Comparison Chart in %
Loading...
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AIM vs. URGN commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Hold and URGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (AIM: $2.68 vs. URGN: $18.34)
Brand notoriety: AIM and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIM: 49% vs. URGN: 102%
Market capitalization -- AIM: $7.26M vs. URGN: $848.48M
AIM [@Biotechnology] is valued at $7.26M. URGN’s [@Biotechnology] market capitalization is $848.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIM’s FA Score shows that 1 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • AIM’s FA Score: 1 green, 4 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, AIM is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIM’s TA Score shows that 3 TA indicator(s) are bullish while URGN’s TA Score has 3 bullish TA indicator(s).

  • AIM’s TA Score: 3 bullish, 4 bearish.
  • URGN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AIM is a better buy in the short-term than URGN.

Price Growth

AIM (@Biotechnology) experienced а 0.00% price change this week, while URGN (@Biotechnology) price change was +2.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.96%. For the same industry, the average monthly price growth was +9.24%, and the average quarterly price growth was +51.43%.

Reported Earning Dates

URGN is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($848M) has a higher market cap than AIM($7.26M). URGN YTD gains are higher at: 72.207 vs. AIM (-86.465). AIM has higher annual earnings (EBITDA): -15.32M vs. URGN (-119.79M). URGN has more cash in the bank: 196M vs. AIM (835K). AIM has less debt than URGN: AIM (2.81M) vs URGN (125M). URGN has higher revenues than AIM: URGN (91.9M) vs AIM (121K).
AIMURGNAIM / URGN
Capitalization7.26M848M1%
EBITDA-15.32M-119.79M13%
Gain YTD-86.46572.207-120%
P/E RatioN/AN/A-
Revenue121K91.9M0%
Total Cash835K196M0%
Total Debt2.81M125M2%
FUNDAMENTALS RATINGS
AIM vs URGN: Fundamental Ratings
AIM
URGN
OUTLOOK RATING
1..100
4416
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6541
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5037

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AIM's Valuation (32) in the null industry is somewhat better than the same rating for URGN (68) in the Biotechnology industry. This means that AIM’s stock grew somewhat faster than URGN’s over the last 12 months.

AIM's Profit vs Risk Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that AIM’s stock grew similarly to URGN’s over the last 12 months.

AIM's SMR Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that AIM’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (41) in the Biotechnology industry is in the same range as AIM (65) in the null industry. This means that URGN’s stock grew similarly to AIM’s over the last 12 months.

URGN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that URGN’s stock grew similarly to AIM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMURGN
RSI
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 14 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DRD28.411.96
+7.41%
DRDGOLD Ltd
RIME2.670.18
+7.23%
Algorhythm Holdings Inc
SN105.90-0.17
-0.16%
SharkNinja
TCPC6.24-0.07
-1.11%
BlackRock TCP Capital Corp
BNR8.93-0.18
-1.97%
Burning Rock Biotech Limited

AIM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AIM has been loosely correlated with CVAC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AIM jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
-6.94%
CVAC - AIM
44%
Loosely correlated
+0.37%
URGN - AIM
39%
Loosely correlated
+6.26%
HOTH - AIM
33%
Loosely correlated
-4.70%
NEVPF - AIM
32%
Poorly correlated
N/A
RLYB - AIM
30%
Poorly correlated
-2.67%
More